Carfilzomib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
lusutrombopag
Thrombopoietin Receptor Agonist · Hematopoietic Agent
Thrombopoietin Receptor AgonistHematopoietic Agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- CarfilzomibSevereDatabaseDDInter
Mechanism
Lusutrombopag is an oral nonpeptide thrombopoietin receptor agonist (TRA) that binds to and activates the TPO receptor, stimulating the production of megakaryocytes and platelets in the marrow.
Indications
chronic liver disease–associated thrombocytopenia in patients with a scheduled procedure
Dosing
- Adult
- 3 mg orally once daily for 7 days, beginning 8–14 days prior to the scheduled procedure. The procedure should be conducted 2–8 days after the last lusutrombopag dose.
Side effects
Serious
- marrow fibrosis
- rebound thrombocytopenia
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about lusutrombopag
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team